J&J(JNJ)

Search documents
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
ZACKS· 2025-04-15 16:15
Core Insights - Johnson & Johnson (J&J) reported first-quarter 2025 earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.57, with a year-over-year increase of 2.2% [1] - Total sales reached $21.89 billion, slightly above the Zacks Consensus Estimate of $21.62 billion, reflecting a 2.4% increase from the previous year [2] - The Innovative Medicines segment showed strong performance, while the MedTech segment missed sales estimates [4][15] Financial Performance - Adjusted earnings, excluding special items, were reported at $4.54 per share, a significant increase of 238.8% year over year [1] - Domestic sales rose 5.9% to $12.3 billion, while international sales declined 1.8% to $9.59 billion [3] - The company raised its 2025 sales guidance to a range of $91.0 billion to $91.8 billion, reflecting an increase from the previous range of $89.2 billion to $90.0 billion [17] Segment Performance - Innovative Medicines segment sales increased by 2.3% year over year to $13.87 billion, outperforming the Zacks Consensus Estimate of $13.46 billion [5] - Key products driving growth included Darzalex, Tremfya, and Erleada, while Stelara sales declined by 33.7% due to biosimilar competition [6][8] - MedTech segment sales were reported at $8.02 billion, up 2.5% year over year, but missed estimates [15] Market Dynamics - The decline in Stelara sales was attributed to the launch of biosimilars, with competition expected to increase in 2025 [9] - The MedTech business faced challenges in the Asia Pacific region, particularly in China, due to government cost containment efforts [16] - J&J's stock has seen a 7.6% increase year-to-date, contrasting with a 6.0% decrease in the industry [22] Future Outlook - The company anticipates growth in the Innovative Medicines segment driven by key products and new drug launches [23] - Despite the positive outlook, challenges such as the Stelara patent cliff and ongoing legal issues related to talc lawsuits may pose significant headwinds [24]
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
ZACKS· 2025-04-15 14:31
Johnson & Johnson (JNJ) reported $21.89 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 2.4%. EPS of $2.77 for the same period compares to $2.71 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $21.62 billion, representing a surprise of +1.26%. The company delivered an EPS surprise of +7.78%, with the consensus EPS estimate being $2.57.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
Proactiveinvestors NA· 2025-04-15 13:43
Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates
ZACKS· 2025-04-15 12:35
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.78%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2 per share when it actually produced earnings of $2.04, delivering a surprise of 2%.Over the l ...
J&J(JNJ) - 2025 Q1 - Earnings Call Transcript
2025-04-15 12:30
Financial Data and Key Metrics Changes - In Q1 2025, Johnson & Johnson reported worldwide sales of $21.9 billion, reflecting a 4.2% increase year-over-year despite a 470 basis point headwind from Stellara [36][37] - Net earnings for the quarter were $11 billion, with diluted earnings per share at $4.54, significantly up from $1.34 a year ago, primarily due to the reversal of a $7 billion talc settlement proposal [38][39] - Adjusted net earnings were $6.7 billion, with adjusted diluted earnings per share at $2.77, representing increases of 1.9% and 2.2% respectively compared to Q1 2024 [38][39] Business Line Data and Key Metrics Changes - Innovative Medicine achieved worldwide sales of $13.9 billion, up 4.2%, with U.S. growth at 6.3% and international growth at 1.5% [40] - Oncology products like Darzalex grew by 22.5%, while Carvicti saw over 100% growth, achieving sales of $369 million [40][41] - MedTech reported worldwide sales of $8 billion, a 4.1% increase, with U.S. growth at 5.1% and international growth at 3% [46] Market Data and Key Metrics Changes - U.S. sales growth was 5.9%, while international sales growth was 2.1%, positively impacted by acquisitions and divestitures [37] - The MedTech segment faced challenges due to one-time events and competitive pressures, particularly in orthopedics, which declined by 3.1% [50][46] Company Strategy and Development Direction - The company plans to invest over $55 billion in the U.S. over the next four years to enhance manufacturing and R&D capabilities [19][20] - Johnson & Johnson aims to exit non-strategic product lines and optimize select sites to improve growth and profitability, with a restructuring program expected to be completed by 2027 [60][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite challenges from Stellara biosimilars and Part D redesign, highlighting a 4.2% growth across Innovative Medicine [10][102] - The company anticipates higher growth in the second half of 2025, driven by new product launches and a strong pipeline [66][71] Other Important Information - The company announced a 4.8% increase in dividends, marking the 63rd consecutive year of dividend increases [22][64] - Johnson & Johnson reversed a $7 billion reserve related to the talc settlement, which is expected to positively impact capital allocation priorities [65] Q&A Session Summary Question: Impact of tariffs on guidance - Management explained that the $400 million in tariffs primarily affects MedTech and includes various tariffs from Mexico, Canada, and China, with limited price leverage available to mitigate these costs [82][86] Question: Gross margins in the quarter - Management noted that gross margins were impacted by Stellara's decline and Part D redesign, with expectations for improvement moving forward [93][96] Question: Stellara biosimilar erosion - Management confirmed that the impact of Stellara biosimilars was in line with expectations, with overall business growth remaining strong despite this headwind [99][102] Question: Recession impact on business - Management indicated that healthcare has proven to be more recession-proof than other industries, with a focus on monitoring job reports as a precursor to healthcare demand [110][112] Question: Section 232 potential pharma tariffs - Management is analyzing the potential impact of Section 232 tariffs and emphasized the importance of partnering with the administration to mitigate vulnerabilities in the healthcare supply chain [117][120]
J&J(JNJ) - 2026 Q1 - Quarterly Results
2025-04-15 12:14
Sales Performance - Total sales for the first quarter of 2025 reached $21,893 million, a 2.4% increase compared to $21,383 million in 2024[3] - U.S. sales increased by 5.9% to $12,305 million, while international sales decreased by 1.8% to $9,588 million[1] - Innovative Medicine segment reported a 2.3% increase in sales, while MedTech segment sales grew by 2.5%[2] - Oncology sales in the U.S. surged by 26.4% to $3,013 million, with international sales increasing by 9.6%[10] - The MedTech segment's total revenue for Q1 2025 was $2,103 million, reflecting a 16.4% increase compared to $1,806 million in Q1 2024[15] - Total MedTech segment sales reached $8,020 million in Q1 2025, a 2.5% increase compared to $7,821 million in Q1 2024[16] - U.S. MedTech sales grew by 5.1% to $4,213 million, while international sales slightly decreased by 0.2% to $3,807 million[16] - The Vision segment in the U.S. reported a 3.4% increase in sales, totaling $566 million, while international sales remained relatively flat with a 0.4% increase[16] Profitability - Gross profit decreased by 2.3% to $14,536 million, with a gross margin of 66.4% compared to 69.6% in the previous year[3] - Net earnings for the first quarter of 2025 were $10,999 million, a significant increase of 237.9% from $3,255 million in 2024[3] - Adjusted net earnings per share (diluted) rose to $2.77, a 2.2% increase from $2.71 in the previous year[5] Expenses and Taxation - The effective tax rate increased to 19.3% from 12.4% year-over-year[3] - Research and development expenses decreased by 8.9% to $3,225 million, representing 14.7% of sales[3] - The company initiated a restructuring program in the MedTech segment, incurring $55 million in expenses during the first quarter of 2025[6] Segment Performance - US sales in the Immunology segment decreased by 10.5% to $2,196 million, while international sales fell by 15.8% to $1,510 million[12] - The Neuroscience segment reported a 8.6% decline in worldwide sales, totaling $1,647 million, with US sales down 8.1% to $968 million[13] - Cardiovascular/Metabolism/Other segment in the US saw a significant increase of 35.4%, reaching $855 million, while international sales decreased by 19.7%[14] - XARELTO sales in the US increased by 33.3% to $690 million, contributing to a total of $690 million worldwide[14] - US sales for STELARA decreased by 29.8% to $981 million, with international sales down 38.9% to $644 million[12] - The Pulmonary Hypertension segment reported a worldwide revenue of $1,025 million, a decrease of 2.3% from $1,049 million in Q1 2024[13] - SPRAVATO sales in the US increased by 45.0% to $276 million, with worldwide sales reaching $320 million, up 41.9%[12] - The company reported a 2.9% decline in US sales for Infectious Diseases, totaling $315 million, while international sales decreased by 1.9% to $487 million[13] Future Projections - Innovative Medicine segment sales for the full year 2024 are projected to reach $2,225 million, with significant contributions from Pulmonary Hypertension products[18] - Rybrevant and Lazcluze generated $93 million in total sales in Q1 2024, with U.S. sales accounting for $36 million[18] - Talvey's sales in the U.S. for Q1 2024 were $50 million, with full-year expectations of $241 million[18] - Other Oncology products generated $328 million in total sales in Q1 2024, with U.S. sales at $93 million[18] - The company anticipates continued growth in the Pulmonary Hypertension segment, with Q1 2024 U.S. sales of $356 million[18] - International sales of Infectious Diseases products reached $1,395 million in Q1 2024, with U.S. sales at $19 million[18] - The overall operational growth for the MedTech segment was 4.1%, excluding currency effects[16]
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga· 2025-04-15 07:33
Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period. Johnson & Johnson projects to report quarterly revenue at $21.57 billion, compared to $21.38 billion a year earlier, according to data from Benzinga Pro. Protagonist Therapeutics, on April 10, announced new data for a pill that trea ...
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Seeking Alpha· 2025-04-11 16:46
Core Viewpoint - The analysis emphasizes the potential of Johnson & Johnson (JNJ) stock as a "Buy" due to its competitive advantages and defensibility in the market [1]. Group 1: Company Analysis - Johnson & Johnson is identified as a high-quality company capable of outperforming the market over the long term [1]. - The analysis focuses on companies with a competitive advantage, referred to as an economic moat, which enhances their market position [1]. - The investment strategy is not limited by market capitalization, allowing for a broader range of investment opportunities from large cap to small cap companies [1]. Group 2: Analyst Background - The analyst has a Master's Degree in Sociology with a focus on organizational and economic sociology, and a Bachelor's Degree in Sociology and History [1].
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
ZACKS· 2025-04-11 16:35
Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its first-quarter 2025 results on April 15. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $21.66 billion and $2.57 per share, respectively. The Zacks Consensus Estimate for J&J’s earnings has declined from $10.58 per share to $10.57 per share for 2025, while that for 2026 has declined from $11.07 per share to $11.02 per share over the past 60 days.Find the latest EPS estimate ...